Equity Overview
Price & Market Data
Price: $1.51
Daily Change: -$0.02 / 1.32%
Daily Range: $1.49 - $1.55
Market Cap: $128,296,096
Daily Volume: 572,222
Performance Metrics
1 Week: 4.14%
1 Month: -37.08%
3 Months: 17.05%
6 Months: -27.05%
1 Year: 17.05%
YTD: -36.02%
Company Details
Employees: 33
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.